Cannara Biotech, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Zohar Krivorot
- Full Time Employees
- 452
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- 333 Decarie Blvd. Suite 200 Montréal QC Canada H4N 3M9
- IPO Date
- Jan 14, 2019
- Website
- cannara.ca
- Similar Companies
- Business
- Cannara Biotech Inc. engages in the indoor cultivation, processing and sale of cannabis and cannabis-derived products in Canada, with real estate operations linked to its Farnham and Valleyfield facilities. Headquartered in Saint-Laurent, Quebec, Canada, Cannara is a vertically integrated producer founded in 2017, operating two large-scale Québec facilities totaling more than 1.6 million square feet and designed to support up to 100,000 kg of potential annualized production capacity. The company markets a portfolio of premium brands including Tribal, Nugz and Orchid CBD, and sells dried cannabis and cannabis derivatives through wholesale and online channels, with a focus on disciplined growth, operational efficiency and price competitiveness enabled by its scalable platform. Cannara reports governance and strategic activity through two segments: Cannabis operations, which cover cultivation, processing and sale of cannabis and derivatives to the Canadian market; and Real estate operations, comprising the Farnham and Valleyfield properties. Recent developments include expanded post-processing capacity at Farnham, preparation of additional grow zones, and a planned Valleyfield processing center to support future expansion and efficiency improvements, alongside ongoing investor relations activities and potential refinements to its brand and product offerings within its Canadian footprint. The company emphasizes strong market share growth, brand-driven sell-through, and capital investments aligned with scalable production and post-processing capabilities to sustain future growth. Cannara’s geographic focus remains Canada, with its headquarters and primary production base in Quebec and operations centered in the province’s cultivation and processing ecosystem. Subsidiaries and related structures support its integrated cultivation, processing, branding, and real estate activities within the Canadian cannabis industry.
Company News
Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec
Video - CEO Clips: Cannara Biotech Graduates to Toronto Stock Exchange
Cannara Biotech Inc. (LOVE) Opens the Market
Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
Cannara Announces Grant of Options and RSUs
Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at Valleyfield
Cannara Biotech Enhances Financial Flexibility Through Strategic Asset Sale
Cannara Secures 5 Key Listings in Québec's New Vape Cartridge Category Including to be Released Live Rosin Vapes
Cannara Biotech to Host Investor Webcast on June 25th, 2025
Cannara Biotech Inc. (LOVFF) Q2 2025 Earnings Call Transcript
Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors
Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike
Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024
Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market
Cannara Biotech Reports Q3 2024 Financial Results
Cannara Biotech Reports Q2 2024 Financial Results
Cannara Biotech Announces Record-Breaking Q1 2024 Results: Continued Robust Growth and Market Expansion